Delineation of gastric cancer subtypes by co-regulated expression of receptor tyrosine kinases and chemosensitivity genes

Shu Chun Li, Rong Ma, Jian Zhong Wu, Xia Xiao, Wei Wu, Gang Li, Bo Chen, Ashok Kumar Sharma, Shan Bai, Bo Ying Dun, Jin-Xiong She, Jin Hai Tang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Chemotherapy plays a key role in improving disease-free survival and overall survival of gastric cancer (GC); however, response rates are variable and a non-negligible proportion of patients undergo toxic and costly chemotherapeutic regimens without a survival benefit. Several studies have shown the existence of GC subtypes which may predict survival and respond differently to chemotherapy. It is also known that the expression level of chemotherapy-related and target therapy-related genes correlates with response to specific antitumor drugs. Nevertheless, these genes have not been considered jointly to define GC subtypes. In this study, we evaluated seven genes known to influence chemotherapeutic response (ERCC1, BRCA1, RRM1, TUBB3, STMN1, TYMS and TOP2A) and five receptor tyrosine kinases (RTKs) (EGFR, ERBB2, PDGFRB, VEGFR1 and VEGFR2). We demonstrate significant heterogeneity of gene expression among GC patients and identified four GC subtypes using the expression profiles of eight genes in two co-regulation groups: chemosensitivity (BRCA1, STMN1, TYMS andTOP2A) and RTKs (EGFR, PDGFRB, VEGFR1 and VEGFR2). The results are of immediate translational value regarding GC diagnostics and therapeutics, as many of these genes are curently widely used in relevant clinical testing.

Original languageEnglish (US)
Pages (from-to)1429-1439
Number of pages11
JournalAmerican Journal of Translational Research
Volume7
Issue number8
StatePublished - Sep 11 2015

Fingerprint

Receptor Protein-Tyrosine Kinases
Stomach Neoplasms
Genes
Chemotherapy
Platelet-Derived Growth Factor beta Receptor
Drug Therapy
Survival
Poisons
Gene expression
Antineoplastic Agents
Transcriptome
Genetic Therapy
Disease-Free Survival
Gene Expression
Testing

Keywords

  • Chemotherapy
  • Co-regulation
  • Gastric cancer
  • Gene expression

ASJC Scopus subject areas

  • Medicine(all)
  • Cancer Research
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Delineation of gastric cancer subtypes by co-regulated expression of receptor tyrosine kinases and chemosensitivity genes. / Li, Shu Chun; Ma, Rong; Wu, Jian Zhong; Xiao, Xia; Wu, Wei; Li, Gang; Chen, Bo; Sharma, Ashok Kumar; Bai, Shan; Dun, Bo Ying; She, Jin-Xiong; Tang, Jin Hai.

In: American Journal of Translational Research, Vol. 7, No. 8, 11.09.2015, p. 1429-1439.

Research output: Contribution to journalArticle

Li, Shu Chun ; Ma, Rong ; Wu, Jian Zhong ; Xiao, Xia ; Wu, Wei ; Li, Gang ; Chen, Bo ; Sharma, Ashok Kumar ; Bai, Shan ; Dun, Bo Ying ; She, Jin-Xiong ; Tang, Jin Hai. / Delineation of gastric cancer subtypes by co-regulated expression of receptor tyrosine kinases and chemosensitivity genes. In: American Journal of Translational Research. 2015 ; Vol. 7, No. 8. pp. 1429-1439.
@article{c62cad0562df47e086b5ab59f6b299e1,
title = "Delineation of gastric cancer subtypes by co-regulated expression of receptor tyrosine kinases and chemosensitivity genes",
abstract = "Chemotherapy plays a key role in improving disease-free survival and overall survival of gastric cancer (GC); however, response rates are variable and a non-negligible proportion of patients undergo toxic and costly chemotherapeutic regimens without a survival benefit. Several studies have shown the existence of GC subtypes which may predict survival and respond differently to chemotherapy. It is also known that the expression level of chemotherapy-related and target therapy-related genes correlates with response to specific antitumor drugs. Nevertheless, these genes have not been considered jointly to define GC subtypes. In this study, we evaluated seven genes known to influence chemotherapeutic response (ERCC1, BRCA1, RRM1, TUBB3, STMN1, TYMS and TOP2A) and five receptor tyrosine kinases (RTKs) (EGFR, ERBB2, PDGFRB, VEGFR1 and VEGFR2). We demonstrate significant heterogeneity of gene expression among GC patients and identified four GC subtypes using the expression profiles of eight genes in two co-regulation groups: chemosensitivity (BRCA1, STMN1, TYMS andTOP2A) and RTKs (EGFR, PDGFRB, VEGFR1 and VEGFR2). The results are of immediate translational value regarding GC diagnostics and therapeutics, as many of these genes are curently widely used in relevant clinical testing.",
keywords = "Chemotherapy, Co-regulation, Gastric cancer, Gene expression",
author = "Li, {Shu Chun} and Rong Ma and Wu, {Jian Zhong} and Xia Xiao and Wei Wu and Gang Li and Bo Chen and Sharma, {Ashok Kumar} and Shan Bai and Dun, {Bo Ying} and Jin-Xiong She and Tang, {Jin Hai}",
year = "2015",
month = "9",
day = "11",
language = "English (US)",
volume = "7",
pages = "1429--1439",
journal = "American Journal of Translational Research",
issn = "1943-8141",
publisher = "e-Century Publishing Corporation",
number = "8",

}

TY - JOUR

T1 - Delineation of gastric cancer subtypes by co-regulated expression of receptor tyrosine kinases and chemosensitivity genes

AU - Li, Shu Chun

AU - Ma, Rong

AU - Wu, Jian Zhong

AU - Xiao, Xia

AU - Wu, Wei

AU - Li, Gang

AU - Chen, Bo

AU - Sharma, Ashok Kumar

AU - Bai, Shan

AU - Dun, Bo Ying

AU - She, Jin-Xiong

AU - Tang, Jin Hai

PY - 2015/9/11

Y1 - 2015/9/11

N2 - Chemotherapy plays a key role in improving disease-free survival and overall survival of gastric cancer (GC); however, response rates are variable and a non-negligible proportion of patients undergo toxic and costly chemotherapeutic regimens without a survival benefit. Several studies have shown the existence of GC subtypes which may predict survival and respond differently to chemotherapy. It is also known that the expression level of chemotherapy-related and target therapy-related genes correlates with response to specific antitumor drugs. Nevertheless, these genes have not been considered jointly to define GC subtypes. In this study, we evaluated seven genes known to influence chemotherapeutic response (ERCC1, BRCA1, RRM1, TUBB3, STMN1, TYMS and TOP2A) and five receptor tyrosine kinases (RTKs) (EGFR, ERBB2, PDGFRB, VEGFR1 and VEGFR2). We demonstrate significant heterogeneity of gene expression among GC patients and identified four GC subtypes using the expression profiles of eight genes in two co-regulation groups: chemosensitivity (BRCA1, STMN1, TYMS andTOP2A) and RTKs (EGFR, PDGFRB, VEGFR1 and VEGFR2). The results are of immediate translational value regarding GC diagnostics and therapeutics, as many of these genes are curently widely used in relevant clinical testing.

AB - Chemotherapy plays a key role in improving disease-free survival and overall survival of gastric cancer (GC); however, response rates are variable and a non-negligible proportion of patients undergo toxic and costly chemotherapeutic regimens without a survival benefit. Several studies have shown the existence of GC subtypes which may predict survival and respond differently to chemotherapy. It is also known that the expression level of chemotherapy-related and target therapy-related genes correlates with response to specific antitumor drugs. Nevertheless, these genes have not been considered jointly to define GC subtypes. In this study, we evaluated seven genes known to influence chemotherapeutic response (ERCC1, BRCA1, RRM1, TUBB3, STMN1, TYMS and TOP2A) and five receptor tyrosine kinases (RTKs) (EGFR, ERBB2, PDGFRB, VEGFR1 and VEGFR2). We demonstrate significant heterogeneity of gene expression among GC patients and identified four GC subtypes using the expression profiles of eight genes in two co-regulation groups: chemosensitivity (BRCA1, STMN1, TYMS andTOP2A) and RTKs (EGFR, PDGFRB, VEGFR1 and VEGFR2). The results are of immediate translational value regarding GC diagnostics and therapeutics, as many of these genes are curently widely used in relevant clinical testing.

KW - Chemotherapy

KW - Co-regulation

KW - Gastric cancer

KW - Gene expression

UR - http://www.scopus.com/inward/record.url?scp=84941211764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941211764&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84941211764

VL - 7

SP - 1429

EP - 1439

JO - American Journal of Translational Research

JF - American Journal of Translational Research

SN - 1943-8141

IS - 8

ER -